SRPT Stock Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$122.89 |
| 52 Week High | US$134.08 |
| 52 Week Low | US$61.28 |
| Beta | 1.01 |
| 1 Month Change | -5.16% |
| 3 Month Change | 7.72% |
| 1 Year Change | 71.71% |
| 3 Year Change | 6.56% |
| 5 Year Change | 102.79% |
| Change since IPO | 215.10% |
Recent News & Updates
Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Jul 19Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation
May 27Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Are Analysts Optimistic?
Feb 23Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
Jan 26Imagine Holding Sarepta Therapeutics (NASDAQ:SRPT) Shares While The Price Zoomed 356% Higher
Dec 21
Should You Review Recent Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
Nov 30Shareholder Returns
| SRPT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.2% | 0.8% | 2.8% |
| 1Y | 71.7% | 7.1% | -9.2% |
Return vs Industry: SRPT exceeded the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: SRPT exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| SRPT volatility | |
|---|---|
| SRPT Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SRPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SRPT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 840 | Doug Ingram | https://www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics, Inc. Fundamentals Summary
| SRPT fundamental statistics | |
|---|---|
| Market Cap | US$10.79b |
| Earnings (TTM) | -US$716.22m |
| Revenue (TTM) | US$876.05m |
12.3x
P/S Ratio-15.1x
P/E RatioIs SRPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRPT income statement (TTM) | |
|---|---|
| Revenue | US$876.05m |
| Cost of Revenue | US$917.93m |
| Gross Profit | -US$41.88m |
| Other Expenses | US$674.34m |
| Earnings | -US$716.22m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.16 |
| Gross Margin | -4.78% |
| Net Profit Margin | -81.76% |
| Debt/Equity Ratio | 358.1% |
How did SRPT perform over the long term?
See historical performance and comparison